Zobrazeno 1 - 5
of 5
pro vyhledávání: '"Rukaiyatu Abdullahi Kirim"'
Autor:
Bulus Adzu, Kudirat Bola Mustapha, Collen Masimirembwa, Obiageri Obodozie, Rukaiyatu Abdullahi Kirim, Karniyus Shingu Gamaniel
Publikováno v:
Avicenna Journal of Phytomedicine, Vol 3, Iss 3, Pp 201-204 (2013)
Objective: To evaluate the effect of NIPRD-AM1 on CYP3A4 in order to generate clinically significant data for its safe and efficacious use. Materials and Methods: NIPRD-AM1 is a phytomedicine developed from aqueous root extracts of Nauclea latifolia
Externí odkaz:
https://doaj.org/article/ed88ed632ef84e0a90842fd4efb3f7dd
Autor:
Olubukola Adebisi Odeniran, Kokonne Elizabeth Ekere, Isa Hayatu Galadima, Rukaiyatu Abdullahi Kirim, Florence David Tarfa, Kudirat Bolanle Mustapha
Publikováno v:
Journal of Phytomedicine and Therapeutics; Vol. 21 No. 2 (2022); 922-930
Cetirizine Hydrochloride is a non-drowsy second-generation antihistamine and a derivative of piperazine with a half-life of eleven hours. It is used to relieve allergy symptoms such as runny nose, sneezing, rhinitis, urticaria and watery eyes. It is
Autor:
Rukaiyatu Abdullahi Kirim, Philip U. Onuche, M. T. Bakare-Odunola, J. A. Ibrahim, K. B. Mustapha
Publikováno v:
Journal of Applied Pharmaceutical Science. :128-132
Autor:
K. B. Mustapha, Margaret Ekpenyong, Rukaiyatu Abdullahi Kirim, Uford S. Inyang, Benjamin U. Ebeshi, Obiageri O. Obodozie
Publikováno v:
European Journal of Drug Metabolism and Pharmacokinetics. 35:103-108
The effect of concurrent administration of a novel phytomedicine, NIPRD-AM1 used for the treatment of malaria on the pharmacokinetics of metronidazole was investigated in healthy volunteers. The study was a completely randomized one, crossover involv
Autor:
Roslyn Thelingwani, Bulus Adzu, Collen Masimirembwa, K. B. Mustapha, Karniyus S. Gamaniel, Rukaiyatu Abdullahi Kirim
Publikováno v:
European journal of drug metabolism and pharmacokinetics. 40(1)
NIPRISAN(®) is a phytomedicine developed from herbal products used in folkloric practice for the management of sickle cell disease (SCD). The effect of NIPRISAN(®) was tested on human cytochrome P4503A4 drug metabolising enzyme to generate clinical